2024 Anti-tumor Drug Innovation Research and Development Conference and "2023 China Anti-tumor New Drug Clinical Research Review" Conference Successfully Held

On August 31, the 2024 anti-tumor drug innovation research and development conference and the press conference of "2023 China anti-tumor drug clinical research review" were held in Shanghai. The conference is jointly sponsored by the Anti-tumor Drug Clinical Research Committee of China Association for the Promotion of Pharmaceutical Innovation (hereinafter referred to as "Anti-tumor Special Committee"), Amida Medical Consulting, Beijing Hisco Clinical Oncology Research Foundation and Oriental Clinical Oncology Research Center. The conference focused on the two major themes of "source innovation in the anti-tumor field" and "challenges and ways out of anti-tumor new drug research and development under the new situation", which attracted the participation of many clinical experts, scholars and enterprise representatives in the industry.

　　Annual Report Released

Song Ruilin, executive chairman of the China Association for the Promotion of Pharmaceutical Innovation, and Li Jin, chairman of the anti-tumor committee and dean of Shanghai Gaobo Cancer Hospital affiliated to China Pharmaceutical University, delivered opening speeches.

Chairman Song pointed out that the release of the "Review of Clinical Research on New Anti-tumor Drugs in China in 2023" (hereinafter referred to as "Review") will provide a scientific basis for future anti-tumor drug research and development and point out the direction for industrial development. President Song called for close cooperation between medicine, research and enterprise in the current era of evidence-based medicine turning to precision medicine.

President Li Jin said that the conference is a concrete action in response to the country's strategic goal of "2030 healthy China. He specifically mentioned the compilation process of the "Review" and said that the book is an important summary of the situation of new drug research and development in the anti-tumor field. He hopes that the release of the "Review" can contribute to the development of new drug creation in China.

Xue Junli, Secretary-General of the Anti-Tumor Committee, presided over the first phase of the meeting and introduced in detail the compilation process of the "Review. She reviewed the work of the anti-tumor committee in promoting the development of clinical research on new drugs in the past few years. At the same time, Secretary-General Xue said that the Review not only covers in-depth analysis of current hot targets, but also provides strategic suggestions for future research and development directions, hoping to help researchers and companies better seize opportunities and optimize resources in the development of new drugs. allocation.

Under the joint witness of President Song Ruilin, Secretary General Feng Lan, President Li Jin, Professor Ma Jun, Director Zhou Caicun, President Han Baohui, Director Zhao Hongyun, Director Liu Aijun and Secretary General Xue Junli, the Review of Clinical Research on New Anti-tumor Drugs in China in 2023 was officially released.

　　Multi-party efforts to build a source of innovation

The second phase of the meeting was presided over by Professor Han Baohui, standing member of the Anti-tumor Clinical Committee of the China Pharmaceutical Promotion Association and vice president and director of Shanghai Chest Hospital.

President Li Jin shared the theme report of "the future prospect of China's anti-tumor drug research and development", deeply analyzed the current complex situation of China's anti-tumor drug research and development, and pointed out that entrepreneurs and the government need to work together to enhance the global competitiveness of China's biopharmaceutical industry. He proposed practical solutions such as commercial insurance support and cross-border data transmission to promote the internationalization of China's new drug creation.

In the theme discussion session, Professor Ma Jun, as the host, discussed with Director Zhou Caicun, President Han Baohui, President Lin Qiang, Director Zhao Hongyun and Dr. Li Jiani, head of Shenghe Pharmaceutical's Product and Innovation System Department, on "The Road to Source Innovation and Development in China's Anti-tumor Field.

The guests agreed that the current lack of source innovation in China's new drug research and development mainly lies in the lack of closeness of the combination of enterprise innovation and clinical research and development. It is recommended to further play the important role of clinical in the drug research and development chain, especially in the early drug research and drug resistance mechanism research. At the same time, it is recommended that enterprises increase investment in translational research and precision medicine. The guests unanimously stated that the high-quality development of China's pharmaceutical innovation must be based on collaboration, transformation and scientific decision-making in order to stand out in global competition.

　　Research and development of new anti-tumor drugs: new technology, new situation and new challenge

The third phase of the meeting was presided over by Feng Lan, Secretary General of China Pharmaceutical Innovation Promotion Association.

Zhou Caicun, vice chairman of the Anti-Tumor Committee and director of the Oncology Department of Dongfang Hospital Affiliated to Tongji University, shared the report on the theme of "New Trends in Lung Cancer Treatment and Drug Research and Development. Director Zhou stressed that the choice of clinical research and development of new drugs should be combined with precision medicine, combined with the actual diagnosis and treatment, control drugs should choose the best treatment in the actual clinical diagnosis and treatment. Director Zhou pointed out that the proportion of different driving genes for lung cancer patients in China is quite different from that in the United States. Drug innovation and research and development cannot blindly follow the United States. It is necessary to develop Chinese drugs that are more suitable for Chinese people from their own perspective.

Ma Jun, vice chairman of the anti tumor committee and director of Harbin Institute of hematology and tumor, shared the report entitled "review and progress of treatment and research and development of blood and lymphatic system diseases. He pointed out that although the treatment of lymphoma has made significant progress with the continuous emergence of advanced therapies such as CAR-T, it still faces challenges such as the complexity of T cell-targeted therapy and the risk of secondary cancer. He specifically mentioned that current medical research should not only focus on the innovation of new drug research and development, but also fully consider the safety of drugs and the long-term quality of life of patients.

Zheng Lei, senior vice president and general manager of greater China, made a report on the theme of "China's strategy and thinking on gene sequencing technology to help global source innovation. She pointed out that gene sequencing has become an important foundation for precision medicine, and the success rate of drug development can be further improved through big data and AI technology. She advocates promoting the application and industrial transformation of biological sample banks, laying a solid foundation for future technological innovation and drug development.

Guo Tong, vice president of business development of IQVIA Greater China, made a theme report on "digital management process of anti-tumor clinical trials. He systematically introduced the three development stages of global digital clinical trials, and pointed out that the core of clinical trial digitization is to improve efficiency, reduce costs and improve data quality. In addition, he discusses the use of decentralized clinical trials globally and in China, showing how digital tools can be used in remote visits, data collection and patient management to provide more flexible and efficient solutions for future clinical trials.

The second round-table discussion on "Challenges and Solutions for Research and Development of Anti-tumor New Drugs under the New Situation" was presided over by President Li Jin. He shared valuable experiences and opinions with Director Cai Qingqing, Director Liu Aijun, Director Xue Junli and Chief Medical Officer Men Yuxin of Haichang Biomedical Technology Co., Ltd. on the design, execution and quality control of clinical trials.

The guests discussed the feasibility of conditional approval of drugs from the perspective of clinical demand and drug differentiation innovation from their respective research fields. At the same time, the panelists unanimously emphasized the important role of "communication" in clinical trials: to maintain the scientific nature of clinical trial protocols requires strengthened communication between sponsors and researchers; to reduce the rate of patient drop-out requires good communication between researchers and patients; The efficient promotion of global multi-center clinical trials requires multi-party communication and cooperation to properly resolve cultural and medical differences between countries.

President Li Jin made a concluding speech for the conference. President Li said that this conference shows that the current anti-tumor drug research and development is moving towards a stage where innovation and challenges coexist. All reports and discussions point to a common theme-how to adopt science and technology in a severe market and regulatory environment. Refined management and innovation to improve the success rate of drug research and development. These discussions will provide valuable experience and enlightenment for the innovation of anti-tumor drugs in China and the world, and inspire us to contribute more to the fight against cancer on the road of continuous progress.